Results: 2

1.
Figure 2.

Figure 2. From: Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study.

Dolutegravir (DTG) fold-change (FC) in 50% inhibitory concentration at baseline, by integrase (IN) mutational pathway at baseline.

Joseph J. Eron, et al. J Infect Dis. 2013 March 1;207(5):740-748.
2.
Figure 1.

Figure 1. From: Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study.

Study design. Subjects received dolutegravir (DTG) 50 mg once daily (cohort I) or DTG 50 mg twice daily (cohort II). In both cohorts, subjects were allocated to 1 of 2 groups on the basis of integrase genotype at screening, to ensure a broad representation of genotypes and a range of phenotypic susceptibility. Cohort II subjects were required to have ≥1 fully active antiretroviral therapy in an optimized background regimen (OBR). Abbreviation: RAL, raltegravir. aQ148H/K/R plus changes in L74, E138, or G140. bSubjects remained on failing background regimen from day 1 to day 10.

Joseph J. Eron, et al. J Infect Dis. 2013 March 1;207(5):740-748.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk